NCT07573215

Brief Summary

This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 1, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 7, 2026

Completed
Last Updated

May 7, 2026

Status Verified

May 1, 2026

First QC Date

May 1, 2026

Last Update Submit

May 1, 2026

Conditions

PDACPDAC - Pancreatic Ductal AdenocarcinomaMetastatic Pancreas AdenocarcinomaPancreatic CancerPancreatic Cancer MetastaticPancreatic Adenocarcinoma MetastaticPancreatic AdenocarcinomaPancreatic Adenosquamous Carcinoma

Keywords

Expanded Access Program (EAP)EAPDaraxonrasibRMC-6236RMC-0706236Metastatic pancreatic adenocarcinomaPancreatic ductal adenocarcinoma (PDAC)RAS(ON) inhibitorUnmet medical needPancreatic cancerRASKRASPancreatic Cancer MetastaticPancreatic Adenocarcinoma MetastaticPancreatic Adenosquamous CarcinomaPancreatic AdenocarcinomaCompassionate Use

Interventions

daraxonrasibDRUG

Oral tablets administered once daily

Also known as: RMC-6236, RMC-0706236

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically or cytologically confirmed PDAC with metastatic disease.
  • Evidence of active disease progression during or following the most recent line of systemic therapy for PDAC, based on investigator assessment.
  • At least one prior line of systemic therapy in the metastatic setting, which must include either a fluoropyrimidine-based or gemcitabine-based regimen.
  • Received and progressed, been intolerant to prior standard therapy, or no longer expected to benefit from standard therapies.
  • Adequate bone marrow, renal, hepatic, and coagulation functions.
  • Ineligible for, or unable to enroll in, another clinical trial of daraxonrasib, if available.
  • Able to take oral medications

You may not qualify if:

  • History of known central nervous system metastatic disease.
  • Concurrent systemic anticancer therapy.
  • Significant cardiovascular disease.
  • Major GI conditions that may affect the ability to take or absorb daraxonrasib (patients with prior Whipple procedure are eligible).
  • Active uncontrolled systemic infection.
  • Major surgery within 28 days before enrollment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Central Study Contacts

Revolution Medicines Study Director

CONTACT

1-844-2-REVMEDmedinfo@revmed.com

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 1, 2026

First Posted

May 7, 2026

Last Updated

May 7, 2026

Record last verified: 2026-05